Concepedia

Publication | Closed Access

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

DOI

189

Citations

17

References

2008

Year

Sébastien J. Hotte, Hal W. Hirte, Eric X. Chen, Lillian L. Siu, Lyly Le, A. Corey, Anne Iacobucci, Martha MacLean, Larry Lo, Norma Lynn Fox,
Clinical Cancer Research

Abstract

Mapatumumab is well tolerated and further evaluation of this TRAIL-R1 targeting agent is warranted.

References

YearCitations

Page 1